Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/14656566.5.10.2115
Reference44 articles.
1. The worldwide prevalence of multiple sclerosis
2. Quantification of impairment in MS: discussion of the scales in use
3. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
4. L’évaluation médico-économique dans la sclérose en plaques
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cost of illness in multiple sclerosis by disease characteristics – A review of reviews;Expert Review of Pharmacoeconomics & Outcomes Research;2021-10-26
2. Análisis del impacto presupuestario de alemtuzumab como terapia de segunda línea, en comparación con natalizumab y fingolimod, en pacientes previamente tratados con interferón beta 1b, diagnosticados con esclerosis múltiple remitente recurrente activa, tratados en la caja costarricense del seguro social;Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish;2019-01
3. Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice;Clinical Therapeutics;2018-06
4. Determinants of high cost in multiple sclerosis patients: a claims and chart review study;Current Medical Research and Opinion;2016-06-25
5. The indirect costs of multiple sclerosis: systematic review and meta-analysis;Expert Review of Pharmacoeconomics & Outcomes Research;2015-07-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3